Vasculogenic Stem and Progenitor Cells in Human: Future Cell Therapy Product or Liquid Biopsy for Vascular Disease

Smadja, David M.

doi:10.1007/978-3-030-31206-0_11

Cited by 25 publications

(22 citation statements)

References 158 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Firstly, the frequency of circulating ECFCs is rather low, ranging from 0.28–15 ECFCs/10 7 [ 112 , 113 ] to 1 ECFC/10 6 –10 8 MNCs [ 59 ]. This amount of ECFCs is insufficient to achieve a therapeutically relevant number of cells for regenerative purposes [ 59 , 110 , 114 , 115 ].…”

Section: Manipulation Of Pro-angiogenic Signaling Pathways To Imprmentioning

confidence: 99%

“…Secondly, the in vivo mobilization of larger amounts of ECFCs in ischemic patients may not produce effective therapeutic outcomes [ 115 ]. Although an increase in circulating ECFCs has been observed upon an ischemic insult, such as AMI [ 97 ], CAD [ 116 ], CLI [ 117 ], forearm ischemia [ 118 ], and pulmonary hypertension [ 119 ], their angiogenic activity may be severely compromised [ 117 , 118 , 119 , 120 ].…”

Section: Manipulation Of Pro-angiogenic Signaling Pathways To Imprmentioning

confidence: 99%

“…Third, ECFCs’ angiogenic behavior is typically compromised in the presence of cardiovascular risk factors that predispose to the onset of ischemic disorders; this further contributes to discouraging the use of circulating ECFCs for autologous cell therapy [ 15 , 59 , 110 , 115 ]. For instance, the frequency and/or vasoreparative potential of circulating ECFCs are remarkably reduced with CAD [ 120 ], aging [ 121 ], diabetes [ 122 ], abdominal aortic aneurysm [ 123 ], venous thromboembolic disease [ 124 ], congenital diaphragmatic hernia [ 125 ], systemic lupus erythematosus [ 126 ], and the pediatric Moyamoya disease (MMD) [ 127 ].…”

Section: Manipulation Of Pro-angiogenic Signaling Pathways To Imprmentioning

confidence: 99%

“…The paucity of ECFCs in peripheral blood represents a major limitation for their therapeutic use; nevertheless, several strategies have been designed to prime ECFCs ex vivo, thereby increasing their proliferation rate and achieving a therapeutically relevant cell dose ( Table 2 ) [ 115 ]. For instance, long-term ECFC expansion can be accelerated when fetal bovine serum in the culture medium is replaced by human platelet lysate [ 137 , 138 , 139 , 140 ].…”

Section: Manipulation Of Pro-angiogenic Signaling Pathways To Imprmentioning

confidence: 99%

See 3 more Smart Citations

Therapeutic Potential of Endothelial Colony-Forming Cells in Ischemic Disease: Strategies to Improve their Regenerative Efficacy

Faris

Negri

Perna

et al. 2020

IJMS

View full text Add to dashboard Cite

Cardiovascular disease (CVD) comprises a range of major clinical cardiac and circulatory diseases, which produce immense health and economic burdens worldwide. Currently, vascular regenerative surgery represents the most employed therapeutic option to treat ischemic disorders, even though not all the patients are amenable to surgical revascularization. Therefore, more efficient therapeutic approaches are urgently required to promote neovascularization. Therapeutic angiogenesis represents an emerging strategy that aims at reconstructing the damaged vascular network by stimulating local angiogenesis and/or promoting de novo blood vessel formation according to a process known as vasculogenesis. In turn, circulating endothelial colony-forming cells (ECFCs) represent truly endothelial precursors, which display high clonogenic potential and have the documented ability to originate de novo blood vessels in vivo. Therefore, ECFCs are regarded as the most promising cellular candidate to promote therapeutic angiogenesis in patients suffering from CVD. The current briefly summarizes the available information about the origin and characterization of ECFCs and then widely illustrates the preclinical studies that assessed their regenerative efficacy in a variety of ischemic disorders, including acute myocardial infarction, peripheral artery disease, ischemic brain disease, and retinopathy. Then, we describe the most common pharmacological, genetic, and epigenetic strategies employed to enhance the vasoreparative potential of autologous ECFCs by manipulating crucial pro-angiogenic signaling pathways, e.g., extracellular-signal regulated kinase/Akt, phosphoinositide 3-kinase, and Ca2+ signaling. We conclude by discussing the possibility of targeting circulating ECFCs to rescue their dysfunctional phenotype and promote neovascularization in the presence of CVD.

show abstract

Section: Manipulation Of Pro-angiogenic Signaling Pathways To Imprmentioning

confidence: 99%

Section: Manipulation Of Pro-angiogenic Signaling Pathways To Imprmentioning

confidence: 99%

Section: Manipulation Of Pro-angiogenic Signaling Pathways To Imprmentioning

confidence: 99%

Section: Manipulation Of Pro-angiogenic Signaling Pathways To Imprmentioning

confidence: 99%

See 2 more Smart Citations

Therapeutic Potential of Endothelial Colony-Forming Cells in Ischemic Disease: Strategies to Improve their Regenerative Efficacy

Faris

Negri

Perna

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…Firstly, the frequency of circulating ECFCs is rather low, ranging from 0.28 -15 ECFCs/10 7 MNCs [123, 124] to 1 ECFC/10 6 -10 8 MNCs [120]. This amount of ECFCs is insufficient to achieve a therapeutically relevant number of cells for regenerative purposes [119,120,125,126].…”

Section: Manipulation Of Pro-angiogenic Signaling Pathways To Improvementioning

confidence: 99%

Therapeutic Potential of Endothelial Colony Forming Cells in Ischemic Disease: Strategies to Improve Their Regenerative Efficacy

Faris

Negri

Perna

et al. 2020

Preprint

View full text Add to dashboard Cite

Cardiovascular disease (CVD) comprises a group of heart and circulatory disorders, which are regarded as a global medical issue with high prevalence and mortality rates. Currently, vascular regenerative surgery represents the most employed therapeutic option to treat ischemic disorders, even though not all the patients are amenable to surgical revascularization. Therefore, more efficient therapeutic approaches are urgently required to promote neovascularization. Therapeutic angiogenesis represents an emerging strategy that aims at reconstructing the damaged vascular network by stimulating local angiogenesis and/or promoting de novo blood vessel formation according to a process known as vasculogenesis. Circulating endothelial colony forming cells (ECFCs), in turn, represent truly endothelial precursors able to aggregate into bidimensional tube networks and to originate patent vessels. Accordingly, ECFCs provide the most rationale and promising cellular candidate for therapeutic purposes. The current review provides a brief outline on the origin and characterization of ECFCs and a summary of the progress in preclinical studies aiming at assessing their efficacy in a variety of ischemic disorders, including AMI, PAD, ischemic brain disease and retinopathy. We also describe how to enhance the vasoreparative potential of ECFCs by boosting specific pro-angiogenic signalling pathways either pharmacologically or through gene manipulation. Taken together, these observations suggest that ECFCs represent a useful strategy to treat ischemic diseases.

show abstract

Molecular analysis and comparison of CD34⁺ and CD133⁺ very small embryonic‐like stem cells purified from umbilical cord blood

et al. 2023

View full text Add to dashboard Cite

Very small embryonic like stem cells (VSELs) are a dormant population of stem cells that, as proposed, are deposited during embryogenesis in various tissues, including bone marrow (BM). These cells are released under steady state conditions from their tissue locations and circulate at a low level in peripheral blood (PB). Their number increases in response to stressors as well as tissue/organ damage. This increase is evident during neonatal delivery, as delivery stress prompts enrichment of umbilical cord blood (UCB) with VSELs. These cells could be purified from BM, PB, and UCB by multiparameter sorting as a population of very small CXCR4+Lin−CD45− cells that express the CD34 or CD133 antigen. In this report, we evaluated a number of CD34+Lin−CD45− and CD133+Lin−CD45− UCB‐derived VSELs. We also performed initial molecular characterization of both cell populations for expression of selected pluripotency markers and compared these cells at the proteomic level. We noticed that CD133+Lin−CD45− population is more rare and express, at a higher level, mRNA for pluripotency markers Oct‐4 and Nanog as well as the stromal‐derived factor‐1 (SDF‐1) CXCR4 receptor that regulates trafficking of these cells, however both cells population did not significantly differ in the expression of proteins assigned to main biological processes.

show abstract

Vasculogenic Stem and Progenitor Cells in Human: Future Cell Therapy Product or Liquid Biopsy for Vascular Disease

Cited by 25 publications

References 158 publications

Therapeutic Potential of Endothelial Colony-Forming Cells in Ischemic Disease: Strategies to Improve their Regenerative Efficacy

Therapeutic Potential of Endothelial Colony-Forming Cells in Ischemic Disease: Strategies to Improve their Regenerative Efficacy

Therapeutic Potential of Endothelial Colony Forming Cells in Ischemic Disease: Strategies to Improve Their Regenerative Efficacy

Molecular analysis and comparison of CD34⁺ and CD133⁺ very small embryonic‐like stem cells purified from umbilical cord blood

Contact Info

Product

Resources

About

Vasculogenic Stem and Progenitor Cells in Human: Future Cell Therapy Product or Liquid Biopsy for Vascular Disease

Cited by 25 publications

References 158 publications

Therapeutic Potential of Endothelial Colony-Forming Cells in Ischemic Disease: Strategies to Improve their Regenerative Efficacy

Therapeutic Potential of Endothelial Colony-Forming Cells in Ischemic Disease: Strategies to Improve their Regenerative Efficacy

Therapeutic Potential of Endothelial Colony Forming Cells in Ischemic Disease: Strategies to Improve Their Regenerative Efficacy

Molecular analysis and comparison of CD34+ and CD133+ very small embryonic‐like stem cells purified from umbilical cord blood

Contact Info

Product

Resources

About

Molecular analysis and comparison of CD34⁺ and CD133⁺ very small embryonic‐like stem cells purified from umbilical cord blood